Now Playing
Opinion|Videos|June 27, 2024
Biomarker Testing and Guideline-Recommended Care in mNSCLC
Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the current NCCN guideline recommendations regarding molecular/genetic testing (NGS, etc.) for newly diagnosed mNSCLC patients?
- Do the NCCN guideline recommendations for molecular/genetic testing and biomarker evaluation differ between squamous and non-squamous non-small cell lung cancer? If so, how, and why?
- What is the rationale and clinical utility of comprehensive biomarker testing in this setting?
Advertisement
Related to this article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5